Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of the Safety and Effectiveness of Oral SFA-002 Compared to Oral Apremilast (Otezla) Tablets and Placebo in Mild to Severe Plaque Psoriasis

NCT06863493 is registered in ClinicalTrials.gov with SFA Therapeutics as lead sponsor.

NCT NCT06863493
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06863493 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of the Safety and Effectiveness of Oral SFA-002 Compared to Oral Apremilast (Otezla) Tablets and Placebo in Mild to Severe Plaque Psoriasis
Lead sponsor
SFA Therapeutics
Phase
Phase 2/3
Overall status
Not yet recruiting
Start date
June 1, 2025
Completion date
September 1, 2026
Enrollment
125 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis (pso)